InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
1
T+90 hit rate
27%
T+90 mean return
-19.6%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Loerop James, Vice-Président Exécutif du Développement Commercial. Insider active across 3 companies, notably Anika Therapeutics, Inc.. Aggregated, 12 reports have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €148k. Activity tracked since 8 July 2021. The latest transaction was disclosed on 1 February 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
15,980 shares@ US$2.4817.1% of flowCommon StockSEC:0001781549-26-000007:0
7,500 sharesCommon StockSEC:0001415889-25-002938:1
11,250 sharesCommon StockSEC:0001415889-25-002938:0
14,750 sharesCommon StockSEC:0001415889-25-002938:2
15,447 shares@ US$2.4816.6% of flowCommon StockSEC:0001415889-25-002938:3
73,750 sharesCommon StockSEC:0001415889-25-000622:0
11,250 sharesCommon StockSEC:0001209191-24-002838:0
14,705 shares@ US$6.797641.5% of flowCommon StockSEC:0001209191-23-047522:0
Ideal exit: 24 May 2024 (T+270)
4,267 shares@ US$13.890924.8% of flowCommon StockSEC:0001209191-23-008451:0
11,250 sharesCommon StockSEC:0001209191-23-006999:0
3,000 shares0Common StockSEC:0001171843-21-004833:0
3,000 shares0Common StockSEC:0001171843-21-004833
12 of 12 declarations
About Loerop James
James Loerop is the EVP of Business Development at Anika Therapeutics, Inc. In this role, he is responsible for formulating and executing the company's business development strategies. James Loerop collaborates closely with internal teams and external partners to identify new market opportunities and strengthen Anika's position in the biotechnology industry. His expertise in business development is crucial for achieving the company's growth objectives.
